Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting.
Mult Scler J Exp Transl Clin
; 5(3): 2055217319875467, 2019.
Article
em En
| MEDLINE
| ID: mdl-31588362
ABSTRACT
BACKGROUND:
Tuberculosis screening is recommended in multiple sclerosis patients starting certain disease-modifying therapies. Disease-modifying therapies may affect interferon-gamma release assay results.OBJECTIVE:
To determine the effects of multiple sclerosis disease-modifying therapies on interferon-gamma release assay results.METHODS:
Indeterminate interferon-gamma release assay results among multiple sclerosis patients were compared across disease-modifying therapies by Fisher's exact test. Logistic regression evaluated the effects of lymphopenia on interferon-gamma release assay results.RESULTS:
A total of 1058 patients underwent interferon-gamma release assay 2.0% (21) positive, 6.1% (65) indeterminate, with 59.4% (628) on disease-modifying therapies. Results were significantly different across disease-modifying therapies (P = 0.002). Absolute lymphocyte count less than 0.5 k/µL had 9.39 times (95% confidence interval 5.2-17.0) increased odds of indeterminate interferon-gamma release assay results.CONCLUSIONS:
Disease-modifying therapies affecting lymphocytes had a higher risk of indeterminate interferon-gamma release assay results.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Diagnostic_studies
/
Prevalence_studies
/
Risk_factors_studies
/
Screening_studies
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article